Topical: SolarazeŽ
Topical gel formulation of diclofenac using Hyaluronan Induced Targeting (HIT) technology
Approved for treatment of pre-cancerous skin condition actinic keratosis
US launch Jan 2002
US market potential estimate: US$250m
Resolution with Bioglan in Dec 2001
Bioglan paid SkyePharma US$12.5m
North American marketing rights transferred to Quintiles for further US$5m
Seeking new European marketing partner